OXLCO vs MIRM Comparison

Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize portfolio's risk adjusted total return, and currently seek to achieve investment objective by investing in structured finance investments, specifically the equity and junior debt tranches of CLO vehicles, which are collateralized by a diverse portfolio of senior secured loans made to companies whose debt is unrated or is rated below investment grade (the Senior Loans) and, to a limited. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.